This trial is testing a new medication, BI 706321, to see if it helps adults with Crohn's disease, in combination with ustekinumab. Participants will take the medication daily for 3 months, then receive ustekinumab injections every 2 months for 9 months.
1 Primary · 7 Secondary · Reporting Duration: Up to 104 days
Experimental Treatment
Non-Treatment Group
50 Total Participants · 2 Treatment Groups
Primary Treatment: ustekinumab · Has Placebo Group · Phase 2
Age 18 - 75 · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: